Biopharmaceutical company Absci has transitioned into a clinical-stage organisation with the dosing of patients in its Phase I clinical trial of ABS-101.
ABS-101 is the company’s investigational anti-TL1A antibody targeting inflammatory bowel disease, engineered using Absci’s generative AI platform.
“We are excited to advance ABS-101 into Phase I clinical trials,” said Andreas Busch, PhD, Absci Chief Innovation Officer. “Designed and optimised using our generative AI platform,…
